Madrigal Pharmaceuticals-2026-JPM.pdf

1、Leading the Fight Against MASHJanuary 12,2026J.P.Morgan 44th Annual Healthcare Conference Bill Sibold,Chief Executive OfficerDave Soergel,M.D.,Chief Medical Officer Forward-looking StatementsThis presentation includes“forward-looking statements”made pursuant to the safe harbor provisions of the Priv

2、ate Securities Litigation Reform Act of 1995,that are based on Madrigals beliefs and assumptions and on information currently available to it but are subject to factors beyond its control.Forward-looking statements reflect managements current knowledge,assumptions,judgment and expectations regarding

3、 future performance or events.Forward-looking statements include all statements that are not historical facts;statements referenced by forward-looking statement identifiers;and statements regarding:potential future growth of Rezdiffra(resmetirom)sales;expected commercial insurance coverage for Rezdi

4、ffra;the expected benefit of Madrigals intellectual property;Madrigals ability to obtain full approval for Rezdiffra in the United States and Europe;expectations regarding Madrigals clinical development plans and related timelines;Madrigals leadership position in the MASH sector;the potential impact

5、 of positive results from the MAESTRO-NASH OUTCOMES trial;the potential benefit of Rezdiffra in patients with compensated MASH cirrhosis;the competitive landscape and market dynamics;estimates of patients diagnosed with MASH and market opportunities;and strategies,objectives and commercial opportuni

6、ties,including potential prospects or results.Forward-looking statements can be identified by terms such as“accelerate,”“achieve,”“allow,”“anticipates,”“appear,”“be,”“believes,”“can,”“confidence,”“continue,”“could,”“demonstrates,”design,”“estimates,”“expectation,”“expects,”“forecasts,”“future,”“goal